Cardiac Implantable Electronic Device-Related Infections by Almqvist, Måns et al.
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
1Chapter
Cardiac Implantable Electronic 
Device-Related Infections
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Abstract
The use of cardiac devices, that is, pacemakers and implantable cardioverter 
defibrillators, has increased, and the incidence will likely continue to increase due 
to an aging population with associated risk factors. Unfortunately, this implies an 
increasing number of complications, including infections. Cardiac device-related 
infection is a dreaded complication causing both increased morbidity and mortality, 
and considerable costs. Because of the presence of a foreign body in subcutane-
ous tissue, vasculature, and the heart, patients with cardiac device systems are at 
increased risk of endocarditis due to microbial agents. In general, an infected device 
system should be removed in its entirety. The timing of reimplantation varies due to 
indication and severity of the infection. Furthermore, the explant procedure may be 
complicated and should be performed by an experienced team including facilities to 
handle life-threatening complications. The subcutaneous implantable cardioverter 
defibrillator or leadless pacemaker can serve as an option in selected cases. This 
chapter will describe clinical aspects of cardiac device-related infections.
Keywords: cardiac device, endocarditis, infection, implantable cardioverter 
defibrillator, pacemaker
1. Introduction
Infective endocarditis (IE) is a potentially lethal disease. First described by 
Osler more than a century ago, it remains associated with a considerable burden 
of complications and death [1–3]. In fact, the incidence has increased over the 
years—in part reflecting a growing number of comorbidities in an aging popula-
tion. Improvements in cardiovascular health care have not only contributed to 
increased life expectancy but also to a growing number of patients living with 
underlying cardiovascular pathologies that constitute risk factors for IE. Thus, 
endocarditis can be described as an adverse consequence of medical advances. This 
is certainly valid in the case of endocarditis affecting cardiac implantable electronic 
devices (CIEDs). Since the introduction of the pacemaker as a routine treatment 
for bradyarrhythmias in the 1960s, a rapid evolution of technology has resulted 
in several new implantable devices. CIEDs also include implantable cardioverter 
defibrillators (ICD) and cardiac resynchronization therapy (CRT). Today, device 
therapy is an essential therapeutic modality of cardiovascular care. It has extended 
the life span of patients and also improved health-related quality of life. Nowadays, 
approximately 1.2 million CIEDs are implanted each year worldwide [4].
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This highly conventional and routine device treatment is however clouded by 
its potentially devastating complications. CIED infection is a severe complication 
associated with high mortality [5, 6]. The implantation rate is increasing glob-
ally and US data indicate that this is coupled with increased implantation in older 
patients with more co-morbidities. An increased use of more complex device 
systems also implies higher risks. All of this contributes to an end result of more 
CIED infections. As the disease panorama and indications are similar in large parts 
of the world, a similar increase outside the US seems inevitable.
A CIED infection can be challenging to diagnose and treat. It may involve the 
generator pocket, the leads, the endocardial structures, or a combination thereof. 
Involvement of endocardial structures including valves implies higher mortality. 
Diagnostic difficulties can be even greater than in IE because echocardiography is 
less accurate, blood cultures are less sensitive, and the diagnosis is sometimes not 
considered because of unspecific symptoms. Attempts to salvage infected devices 
are often unsuccessful. In this chapter, we present an outline of current recommen-
dations regarding prevention, diagnostics, and management of CIED infections.
2. Technology and terminology
Cardiac device management involves many technical details. For those less 
familiar with these procedures, we recommend the supplementary appendix of a 
recent review [7]. In addition to an outline of the generators, leads, and materials 
used in CIEDs, it also describes the normal step-by-step procedures of implanting, 
revising, and removing CIEDs. Abbreviations are both abundant and inevitable in 
this field and are summarized at the end of this chapter.
3. Definition and categorization of CIED infection
There are no universally agreed definitions of CIED infection. Previously used 
definitions have varied, but common starting points have been the site or sites of 
infection on one hand and the signs of probable infection on the other [8, 9]. One 
common and theoretically simple distinction is between local device infection and 
infection also affecting the blood stream, leads, and/or cardiac valves. However, in 
clinical practice, it is sometimes difficult to differentiate between these categories 
[5]. The lack of a golden standard calls for a clear presentation of used criteria. Our 
proposed classification, summarized below, is a synthesis of earlier studies, recom-
mendations, and guidelines [7, 10, 11].
In short, we suggest six different categories relevant when CIED infection is 
considered. These are presented in Table 1, besides basic strategies for device and 
antibiotic management. The first of three categories involving the generator pocket 
is not a definite infection but rather early post-implantation inflammation. These 
superficial signs of wound inflammation are expected to wear off shortly, when 
suspected causes such as sutures or dressing are removed. However, as they also can 
be an early sign of infection, close observation is recommended.
Actual infections can be categorized as complicated or uncomplicated 
pocket infection based on whether they also involve blood stream infection. 
Echocardiography and the modified Duke criteria can be used to classify more exten-
sive infections: suspected or definite lead infection (CIED-LI), and CIED-associated 
infective endocarditis affecting the heart valves (CIED-IE) [12]. A large proportion 
of patients end up as “possible CIED-LI”. Diagnosing a definite and isolated CIED-LI 
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Diagnostic classifications Device an antibiotic strategy Treatment duration***
Early post-implantation 
inflammation
Erythema near the incision site 
within 30 days of implantation
WITHOUT any of the following:
- purulent exudate,
- dehiscence,
- fluctuance,
- systemic signs of infection*
A small area (<1 cm) of erythema 
and purulence next to a stich,  
(stich abscess), is also included in 
this category.
- No need for device extraction.
- Remove suspected cause (stitches 
or local dressing/skin preparation)
- Consider observation only or short 
oral empiric antibiotic therapy and 
expect clinical resolution within 
2 weeks.
Close observation as this can be early 
signs of pocket infection.
Consider 7–10 days 
of flucloxacillin. For 
penicillin-allergic or 
MRSA-colonized patients, 
consider clindamycin.
Pocket infection—uncomplicated
One or more of the following:
- spreading cellulitis around the 
pocket, or
- incision site purulent exudate 
(excluding stitch abscess), or
- wound dehiscence, or
- erosion through skin with 
exposure of generator or leads,**  
or
- fluctuance (abscess) or fistula 
formation
AND: negative blood cultures
AND: no signs of systemic 
infection
- Device removal recommended
- Commence intravenous empiric 
antibiotic therapy targeting 
Gram-positive (including MRSA) 
bacteria. (Treatment for Gram-
negative bacteria will depend on 
susceptibility testing after blood 
cultures for this group).
- Start targeted treatment after 
results from blood cultures.
10–14 days iv (if no 
complications occur)
Pocket infection—complicated
As uncomplicated pocket 
infection, but WITH:
- positive blood cultures, or
- evidence of lead or endocardial 
infection, or
- symptoms/signs of systemic 
infection.
- Device removal recommended
- Commence intravenous empiric 
antibiotic therapy targeting both 
Gram-positive (including MRSA) 
and Gram-negative bacteria.
- Start targeted treatment after 
results from blood cultures.
Treat as CIED-IE or 
CIED-LI depending on the 
nature of complication.
Definite CIED lead infection 
(CIED-LI)
Symptoms/signs of systemic 
infection
NO signs of generator pocket 
infection
AND: echocardiography 
consistent with lead vegetations
AND: presence of major Duke 
microbiological criteria [12]
OR:
Symptoms/signs of systemic 
infection
NO signs of generator pocket 
infection
AND culture, histology, or 
molecular evidence of infection 
on explanted lead
- Device removal recommended
- Commence intravenous empiric 
antibiotic therapy targeting both 
Gram-positive (including MRSA) 
and Gram-negative bacteria.
- Start targeted treatment after 
results from blood cultures.
For isolated CIED-LI 
consider short course, 
2 weeks of treatment 
after device removal.
If any uncertainty (as 
when tricuspid valve 
is not normal or “ghost 
lesions” remain after 
device removal): treat as 
CIED-IE.
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is difficult, but possible and would require a structurally normal tricuspid valve that 
remains normal after device extraction and no findings suspicious of pocket infec-
tion. Cases with occult bacteremia and neither proof of CIED infection nor alterna-
tive sources of infection, resolving after CIED extraction, are reasonable to title 
probable CIED infection. It may take time and sometimes also device removal before 
a definite diagnosis is established. However, the proposed categories may be relevant 
before that, as a way to structure early management. Clinical systemic signs of infec-
tion include rigors, fever, embolic phenomena, and improvement after treatment.
4. Epidemiology
The last decades have seen a steady increase in the number of patients with CIEDs 
[13–15]. Originally made up mostly of pacemaker implants, the continuing increase 
today is largely due to rising implantation rates of ICD and CRT devices [16]. Using 
current evidence to determine the true incidence of CIED infection is hard, as there 
is no uniform or mandatory reporting, no universal definition of how to classify the 
disease and many differences between studies regarding the time frame for measured 
incidence. Reviews of the literature suggest an overall incidence of CIED infection 
of 0.5–2.2%, based on different follow up periods from 6 weeks to 11 years [7]. Some 
studies instead report incidence per 1000 device years. Three large registry studies of 
pacemaker and ICD patients report 1.8-3.1 per 1000 device years [17–19].
Diagnostic classifications Device an antibiotic strategy Treatment duration***
Possible CIED-LI:
Symptoms/signs of systemic 
infection
AND: echocardiography consistent 
with lead vegetations
NO major Duke microbiological 
criteria present
OR:
symptoms/signs of systemic 
infection
AND: major Duke criteria present
NO echocardiographic evidence of 
lead vegetations
- Consider device removal during 
continued observation with repeated 
echography and repeated blood 
cultures. (For details about patient 
evaluation, see 8. Diagnosis)
- Commence intravenous empiric 
antibiotic therapy targeting both 
Gram-positive (including MRSA) 
and Gram-negative bacteria.
- Start targeted treatment after 
results from blood cultures.
Continue initial iv 
treatment until diagnosis 
is established or ruled out.
CIED-associated endocarditis, 
CIED-IE
Duke criteria for definite 
endocarditis satisfied, with 
echocardiographic evidence of 
valve involvement
- Device removal recommended
- Commence intravenous empiric 
antibiotic therapy (Table 5) 
targeting both Gram-positive 
(including MRSA) and Gram-
negative bacteria.
- Start targeted treatment after 
results from blood cultures.
Native cardiac structures 
involved: 4 weeks iv
Extracardiac foci (e.g. 
skeleton): 6 weeks iv
Probable CIED infection
Occult bacteremia, neither proof 
of CIED infection nor alternative 
sources of infection but resolving 
after CIED extraction.
- Device removal after thorough 
evaluation and exclusion of 
alternative sources of bacteremia.
- Antimicrobial treatment, as 
CIED-LI.
Treat as CIED-LI.
*Clinical systemic signs of infection include rigors, fever, embolic phenomena, and improvement after treatment.
**In some guidelines, device erosion is described as an entity of its own, as this always means that the system will be 
infected, regardless of symptoms.
***Consider day 1 as the first day of appropriate antimicrobials unless persistently bacteremic on therapy.
Table 1. 
Adopted from Sanoe et al. [7].
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As new surgical procedures mature, implantation volumes increase, and the 
operating staff becomes more skilled, it is often reasonable to expect that the inci-
dence of complications will decrease [20]. For CIED infections however, the oppo-
site has been the case. Despite the variations in reported incidence and technique 
of reporting incidence, there are consistent results from several long-term registry 
studies showing increasing infection rates over time [9, 13, 18, 20–22]. These studies 
display not only the well-known trend of increasing implantation rate, accentuated 
by wider indications for ICD treatment, but also an unproportional increase in 
CIED infections. Furthermore, they report higher incidence of infection for ICDs 
and CRT compared to pacemakers and for device revisions (such as upgrades or 
replacements) compared to de novo implantations [23, 24].
A clarifying example is a study of US discharge registries 1993–2008; during the 
16-year study, implantation of pacemakers increased by 45% and ICDs by 504% and 
the total increase in all CIED implantation was 96%. The incidence of CIED infection 
increased by 210% to 2.41% between 1993 and 2008. The rate of infection was fairly 
constant up to 2004 when a marked increase occurred. The study revealed a parallel 
increase in four comorbidities (renal failure, heart failure, diabetes, and respiratory 
failure) among the patients starting in 2004 [13]. This shift also coincided fairly 
close in time with the introduction of new, broader indications for ICD treatment.
This resulted in speculations about comorbidities, together with the risks of 
more complex devices, explaining the increase in CIED infections [13]. As neither 
the aging population with more comorbidities nor the wider indications for ICDs 
are temporary phenomena, a conclusion has been that this has set the stage for 
further increases in CIED infection rates, making the study of risk factors more 
relevant than ever [14].
5. Predictors for CIED infection
Device-related infections are the result of an interaction between different types 
of risk factors—related to the patient, the implantation procedure, the microbe, 
or the device itself [11]. These factors predispose to device infection by either 
increasing the risk of generator or lead contamination at the time of implantation or 
increasing the risk of bacteremia from a distant source with hematogenous seeding 
of device leads [25]. Establishing risk factors is central for prevention and numerous 
risk factors have been identified (Table 2). The evidence supporting these factors 
varies and their combined effect is not easily quantifiable.
5.1 Risk factors related to patient, device, and procedure
A systematic review concluded that the three most consistently identified risk 
factors were the number of prior procedures, their complexity, and lack of anti-
microbial prophylaxis [7]. The importance of antibiotic prophylaxis has also been 
showed in randomized controlled trials [11].
In a meta-analysis of 60 studies (180,000 patients), the most significant 
patient-related risk factors were diabetes mellitus, end-stage renal disease, chronic 
obstructive pulmonary disease, corticosteroid use, previous device infection, renal 
insufficiency, malignancy, and congestive heart failure. Other significant risk fac-
tors were symptomatic heart failure, preprocedural fever, anticoagulant drug use, 
heparin bridging, and chronic skin disorders. Procedural risk factors identified were 
postoperative hematoma, reintervention for lead dislodgement, device revision/
replacement, lack of antibiotic prophylaxis, temporary pacing before the procedure, 
generator exchange, and inexperienced operator (<100 procedures). Significant 
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device-related risk factors were abdominal generator pocket, presence of epicardial 
leads, and positioning of two or more leads [26].
Although this meta-analysis did not show higher infection risks for ICDs 
compared to pacemakers, there are numerous other studies indicating such a risk, 
and a generally higher risk with more complex devices including CRT [18, 27–29]. 
Even though it is hard to exactly quantify the difference in risk of infection with an 
ICD or CRT compared to a pacemaker, it is clear that more complex devices should 
be regarded as a risk factor [11].
Several risk factors are linked to the reopening of the device pocket, for example 
during upgrades, which increases the risk of introducing bacteria—highlighting 
problems with today’s frequent upgrades and recalls.
Several summaries of known risk factors attribute age as a risk factor [11, 25, 
30]. However, it is not certain that it is a fully independent factor and some studies 
show contradicting results, for example, the meta-analysis mentioned above [17, 
26]. As old age has been consistently associated to more co-morbidities and more 
complex devices, we have chosen to list “old age and comorbidities” as a risk factor 
[11]. There are also uncertainties regarding male sex that has been listed as a risk 
factor of infection in a few studies [7]. Reopening of the pocket is linked to several 
risk factors.
5.2 Microbe-related risk factors
Studies point to a risk of CIED infection as high as 35–45% when Staphylococcus 
aureus (S. aureus) is found in blood cultures [8, 29], 30% with other Gram-positive 
cocci [31], and 6% with blood cultures with Gram-negative bacteria [32]. Hence, 
the finding of either S. aureus or other Gram-positive cocci in blood cultures is in 
itself a substantial risk factor for CIED infection [7].
Patient-related risk factors: Procedure-related risk factors:
Age and comorbidities Pocket hematoma
Renal failure Device replacement versus de novo implant
End stage renal disease/hemodialysis Extended procedure
Diabetes mellitus Inexperienced surgeon
Heart failure Lack of prophylactic antibiotics
Chronic obstructive pulmonary disease
Temporary pacing Device-related risk factors:
Periprocedural fever (within 24 h) History of multiple device-related procedures
Malignancy ≥2 leads
Skin disorder ICD/CRT (compared to pacemaker)
Prior CIED infection Epicardial lead(s)
Anticoagulation Abandoned lead(s)
Immunosuppressive drug/stat Recent device manipulation
Microbe-related risk factors:
S. aureus and other gram-positive cocci
Existence of central venous catheter
Postoperative wound infection
Table 2. 
Risk factors for CIED infection [7, 11, 14, 25].
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5.3 Risk factors associated with early versus late onset infections
Studies on infections of ICD systems suggest that there are differences between risk 
factors as to whether they increase the risk of early onset infections (within 6 months 
of implantation) or later infection. In one study, epicardial leads and postoperative 
wound complications, such as pocket hematoma, were associated with early infection 
while the length of hospitalization and chronic obstructive pulmonary disease was 
associated with later infection. A more general interpretation of this has been sug-
gested; circumstances that increase the probability of pocket contamination in the 
postoperative period are more likely to be associated with early onset infection, while 
overall poor health of the patient increases the risk of late onset infection [33]. Attempts 
have also been made to find useful differences between pathogens related to early 
versus late onset infections, yet without clinically significant findings [34]. Although 
these efforts to describe patterns, typical of early versus late infections, can increase the 
understanding of the pathogenesis and prevention, there are yet no simple implications 
for management or other obvious clinical benefits of making such a division.
6. Mortality
Reviews of current evidence have found all-cause mortality to be substantial, 
ranging from 0% to 35%, with big variation probably due to different proportions 
of patient comorbidities between the studies and differences related to devices 
or the definition of CIED infection [7]. The high mortality figures do not only 
reflect the acute effects of the infection; a high proportion of the reported deaths 
are related to cardiac and other noninfection causes. This is also coherent with the 
observation that mortality is up to threefold higher when longer follow-up periods 
are compared to in-hospital or 30-day mortality [7]. Another observation has been 
Patient-related risk factors Procedure-related risk factors
Abnormal renal function CRT device
Older age Complicated device removal
Abnormal right ventricular function De novo implant
Corticosteroid therapy Epicardial right ventricular pacing system in those 
undergoing reimplantation
Endocarditis Late removal (versus immediate)
Heart failure System upgrade/revision
Length of time lead in-situ
Medical therapy
Metastatic malignancy
Moderate/severe tricuspid regurgitation
Pathogen other than a coagulase negative 
Staphylococcus
Pre-reimplantation elevation of C-reactive 
protein
Systemic embolization
Thrombocytopenia on admission
Adapted from Sandoe et al [7].
Table 3. 
Risk factors for mortality in CIED infections.
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that studies including only CIED endocarditis report higher mortality (25–29%) 
than studies of infections localized to the device pocket [7].
Studies of mortality often focus on finding risk factors of mortality, and the 
most frequently reported appear to be abnormal renal function, endocarditis, and 
old age [35–37]. Conditions often associated with endocarditis (systemic emboliza-
tion, tricuspid regurgitation) have also been noted as risk factors of mortality. 
Another risk factor is the identified microbe, where S. aureus is associated with an 
increased mortality [38, 39].
Table 3 shows risk factors for mortality in CIED infection as presented by 
Sandoe et al. [7]. Included are also factors related to device types and whether the 
device is extracted or if the patient receives medical therapy alone. This is discussed 
further under “Management”, but in short, device removal is clearly associated to 
lower mortality [40]. Although there are possible fatal complications from device 
removal, the mortality associated with delaying this procedure is even higher [41]. 
Therefore, there is no indication for extraction as strong as infection [11, 42].
7. Pathogenesis
There are two basic mechanisms of infection, either bacterial contamination at 
the time of implant or hematogenous seeding of the device during bacteremia from 
a distant focus of infection [5].
Excluding rare cases of contamination during manufacturing, it can occur periop-
eratively by anyone handling the device or via the air of the operation theater. Without 
ventilation with laminar flow, it is likely that coagulase-negative staphylococci on skin 
squamae, either from the patient or any of the operating staff, are present in the air. 
An example of this is the en passant finding in one study where 14 unused sterile leads 
were placed on the operation table during a CIED implantation. One of the leads was 
positive for Staphylococcus epidermidis after culturing [7, 43]. During implantation 
and possible later manipulations or revisions, skin incisions always carry the risk of 
skin flora contaminating the wound and eventually the device [7, 20]. It is a com-
mon notion that most CIED infections are the result of contamination at the time of 
implantation, which is supported by the proven effect of surgical site prophylaxis [16].
The alternative, and less common, pathway involves hematogenous seeding 
from a distant focus. In this case, the type of pathogen is critical to the risk of infec-
tion with S. aureus conferring the highest risk, whereas the risk of CIED infection 
from gram-negative bacteremia is low [20].
The common conceptual separation of local device pocket infection from infec-
tion involving leads and bacteremia serves a purpose for describing pathogenesis or 
planning preventive strategies. In practice, it is however often hard to differentiate 
between the two [5]. Once the generator pocket is infected, bacteria can migrate 
along the leads to finally reach intracardiac structures. And although pocket infec-
tion most often is due to perioperative contamination, hematogenous seeding to the 
pocket is also a possibility [14]. The eventual consequence of CIED infection can 
be the forming of vegetations anywhere on the lead and on the tricuspid valve as 
well as the right atrial or ventricular endocardium. Septic pulmonary embolism is a 
frequent complication of device endocarditis [5].
However, pathogenesis cannot be reduced to blood stream or wound contamina-
tion. It is the result of specific interactions between the device, the microbe, and the 
host [14]. Risk factors related to the patient (host) and device have been discussed 
in earlier sections. Additionally, there are specific device factors related to surface 
features and chemical interactions between pathogens and devices affecting pathogen 
adherence. The development of devices with better surface properties in this regard 
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is an important topic under current exploration, although not currently relevant in 
clinical practice, and therefore beyond the scope of this chapter [7, 11, 16, 20]. Finally, 
there are specific virulence factors, all related to microbial ability to adhere to device 
surfaces that are crucial for establishing CIED infection. The most important of these 
is the ability to form biofilm [20, 25, 44]. This reduces the effectiveness of the normal 
immune system response to infection, supplies a barrier against antibiotic penetration, 
and (by metabolic downregulation) makes bacteria less susceptible to antibiotics.
8. Diagnosis
The signs and symptoms of CIED infection depend on the location of the 
infected part of the device, but establishing the diagnosis can sometimes be chal-
lenging with a variety of manifestations. Fever is present in most cases. It is reason-
able to always consider device infection for patients with CIEDs and unexplained 
fever, keeping in mind that a blunted fever response is common among the elderly 
[5]. In some cases, with typical symptoms of localized generator pocket infection, 
diagnosing CIED infection is simple. In other cases, the symptoms can be extremely 
vague despite extensive infection, often resulting in diagnostic delays. As with other 
types of endocarditis, diagnosis is not built on a single test, but rather evaluation of a 
pattern of signs and investigations where echocardiography and blood cultures play 
a fundamental role. Sometimes, S. aureus bacteremia can be the only sign of device 
infection [5]. A central recommendation in guidelines is also that the patient with 
suspected CIED infection should be evaluated by a multidisciplinary team [14].
8.1 Clinical presentation
The most common type of CIED infection (~60%) is a generator pocket infection 
with symptoms of localized inflammation including erythema, pain, swelling, warmth, 
erosion, and purulent drainage or skin dehiscence [45]. In less than half of these cases, 
there are also systemic signs of infection or positive blood cultures [25, 45]. Often, these 
signs are easily identified, motivating the patient to seek medical attention. But some-
times, the symptoms are more subtle, presenting soon after implantation and thereby 
hard to differentiate from pure postoperative inflammation, skin reactions to dressings, 
disinfection agents, and sutures or a restricted and superficial infection [7, 11].
A second major manifestation is that of infection affecting either cardiac valves, 
device leads, or a combination of these two (CIED-IE or CIED-LI). This accounts 
for 10–23% of all CIED infections [25, 46]. Many of these patients have typical signs 
of systemic infection, presenting with fever, rigors, malaise, fatigue, or anorexia. 
Most, but not all, show positive blood cultures [11, 45]. Parallel symptoms of device 
pocket infection make the diagnosis easier, but this is not always the case. Instead, 
the presence of a CIED is often disregarded by the first doctor seeing the patient 
[24]. Major diagnostic tools recommended by guidelines are cardiac imaging, 
repeated blood cultures and use of the modified Duke criteria (Table 4) [7, 12].
In the case of cardiac vegetations, the tricuspid valve is the most common site, but 
vegetations may also appear on both the pulmonic and left-sided valves. S. aureus is 
the most common pathogen. In this patient group, it is common with symptoms or 
radiographic findings indicating septic embolism to the lungs (~40%) as well as other 
organs (18%), and occasionally distant abscess formation [46–48]. Possible embolic 
phenomena are important to keep in mind, as secondary foci of infection, such as 
vertebral osteomyelitis or discitis, can be the main symptom presented by the patient 
[7, 47]. Other possible sites of metastatic abscesses are brain, liver, kidney, and spleen. 
In some cases, it will be hard to distinguish if a distal site of infection is the result of 
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hematogenous seeding from a cardiac device or if the opposite is true [25]. Less than 
10% present with septic shock, usually caused by virulent pathogens such as S. aureus 
or Pseudomonas aeruginosa [7, 44]. Less virulent pathogens are generally associated 
with a more subacute or chronic presentation. In rare cases, this can be coupled with 
immune-complex mediated conditions such as nephritis or vasculitis [44].
In contrast to the diversity of symptoms mentioned above, occult bacteremia (or 
in rare cases fungemia) without localized symptoms at the generator pocket repre-
sents a diagnostic challenge primarily by the absence of findings [11, 25]. Studies 
indicate that laboratory abnormalities are present in less than half of the cases of 
CIED infection, hence normal laboratory results should not rule out CIED infection 
[9, 25]. Distant foci of infection could result in hematogenous seeding of the device 
but should not always be interpreted as evidence of actual CIED infection. To avoid 
misdiagnosis and unnecessary and riskful extractions, an algorithm for managing 
bacteremia among CIED patients has been presented by DeSimone and Sohail [49].
Except for these three main presentations, there are occasional cases of device 
erosion through the skin with neither positive blood cultures nor any other local 
inflammatory changes. Usually, erosion is a slow process of fat necrosis and migra-
tion from deeper layers of the skin and seldom presents shortly after implantation. 
Duke criteria
Major Definite endocarditis
Blood culture positive for IE - 2 major criteria; or
Evidence of endocardial involvement - 1 major criterion and 3 
minor criteria; or
Echocardiogram positive for IE - 5 minor criteria
New valvular regurgitation (worsening of pre-existent murmur not 
sufficient)
Possible endocarditis:
Minor - 1 major and 1 minor 
criterion
Predisposition (predisposing heart condition, iv drug use) -3 minor criteria
Fever (>38°C)
Vascular phenomena, major arterial emboli, septic pulmonary infarcts, mycotic aneurysm, intracranial 
hemorrhage, conjunctival hemorrhage, and Janeway lesions
Immunologic phenomena: glomerulonephritis, Osler’s nodes, Roth´s spots, and rheumatoid factor
Microbiological evidence: positive blood culture but does not meet a major criterion or serological evidence 
of active infection with organism consistent with IE
Microorganisms consistent with IE: (positive results from 2 separate blood cultures required)
- Streptococcus viridans
- Streptococcus bovis
- HACEK group (Haemophilus spp., Aggregatibacter, Cardiobacterium, Eikenella, Kingella)
- Staphylococcus aureus
- Community-acquired enterococci, in the absence of a primary focus
Or:
Microorganisms consistent with IE from persistently positive blood cultures, defined as follows: at least two 
positive cultures of blood samples drawn >12 h apart, or
all of three or a majority of ≥4 separate cultures (with first and last sample drawn at least 1 h apart)
Single positive blood culture for Coxiella burnetii or antiphase 1 IgG antibody titer >1:800
Table 4. 
The Duke criteria, adapted from Li et al. [12].
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The exact cause often remains unclear but can be low grade device infection, other 
local infections or mechanical factors alone [11]. Whenever a generator or lead has 
eroded through the skin, the whole device system should be regarded as infected [7].
8.2 Diagnostic challenges
Beyond the typical and distinct clinical manifestations, there are also many cases 
with scarce or misleading symptoms. One study reports that many diagnostic delays 
are related to the fact that CIED infection was not considered in the original differ-
ential diagnosis, for instance, when device patients present with mainly respiratory 
or rheumatic symptoms that are interpreted as bronchitis [5, 47]. Other reasons for 
delay could be that possible hints about the diagnosis were disregarded, for instance 
positive blood cultures for Staphylococcus epidermidis first considered to represent 
contamination. Sometimes, the diagnosis was taken into consideration, but wrongly 
excluded without adequate investigations, such as a negative transthoracic echocar-
diography (TTE) being interpreted as sufficient for excluding the diagnosis [47].
8.3 Microbiology and adequate sampling
A series of studies consistently show that staphylococci and Gram-positive 
bacteria in general are responsible for most CIED infections. Methicillin resistance 
among S. aureus has been reported to various extents, depending on geographic and 
individual factors [5]. We found the figures of the prevalence of respective patho-
gens fairly consistent with the results of prior studies and systematic reviews [7, 9, 
11, 25, 45, 47, 50–52]. Consistent are also reports of negative cultures despite clinical 
infection. A reason for this may be previous antibiotic treatment and fastidious 
microbes [25]. Negative blood cultures should be interpreted with caution and 
exclusion of infection should not rely exclusively on cultures.
At least two sets of blood cultures (including aerobic and anaerobic cultures) are 
recommended before starting antibiotic therapy. For patients presenting with acute 
symptoms, ideally the two sets should be taken at different times within 1 h from 
peripheral sites. If the clinical presentation is chronic/subacute, guidelines recom-
mend three sets of cultures to be taken from peripheral sites with >6 h between each 
sample, before antibiotic therapy is started [7]. The point of taking multiple cultures 
with certain waiting periods is hopes of improved sensitivity and the ability to dif-
ferentiate between transient and persistent bacteremia. Consistently positive blood 
cultures with the same pathogen are highly indicative of CIED infection. If purulent 
drainage is present from the device pocket, a culture can be very useful and more 
sensitive than other pocket cultures. Percutaneous aspiration of the pocket should, 
however, not be done because of the risk of introducing microorganisms and possibly 
causing device infection [14]. When a device is removed, device pocket swabs and 
tissue culture as well as both proximal and distal lead cultures should be obtained 
[11]. The lead-tip cultures should be interpreted with caution if extracted through an 
infected device pocket because of the risk of contamination. Possible femoral extrac-
tion would reduce this risk. The clinical situation when lead tip cultures interpreted 
as unequivocally significant is when there is no sign of pocket infection [25, 50]. After 
device removal, the recommendation is to obtain new blood cultures after 48–72 h.
8.4 Cardiac imaging
Echocardiography is a cornerstone for diagnosing CIED infection, visualizing 
lead or endocardial vegetations, and estimating valve regurgitation and vegeta-
tion size. TTE is superior for pericardial effusion and estimations of ventricular 
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function and pulmonary pressure. TTE is also convenient for repeated monitoring 
of vegetations and cardiac function before or after extraction. Transesophageal 
echocardiography (TEE) is however superior for diagnosing lead and endocardial 
infection (CIED-LI, CIED-IE), visualizing vegetations, valves and parts of the 
lead that are difficult to see by TTE. It is also superior for visualizing left-sided 
endocarditis and perivalvular abscesses. For the diagnosis of CIED-IE, the sensi-
tivity of TEE is >90%, compared to 22–43% for TTE [7]. Hence, both modalities 
should be used, but in this complimentary manner. Despite the high sensitivity 
of TEE, it is important keeping in mind that a normal echocardiography does not 
completely rule out the possibility of CIED infection [5, 7, 10, 11, 14, 30].
It has been demonstrated that TEE cannot distinguish vegetations from sterile 
thrombi [14, 30]. In studies validating TEE, 5–10% of identified lead masses, first 
described as vegetations, were concluded to represent incidentally found thrombi 
[53, 54]. This underlines the importance of a thorough multidisciplinary evaluation 
using the sum of all findings to assess the patient; masses found on leads in patients 
without symptoms of infection or positive blood cultures should consequently not 
be treated with device extraction and antibiotics, but possibly anticoagulants [10].
New imaging modalities (18F-FDG positron emission tomography/computerized 
tomography, 99mTcHMPAO-WBC) have been studied in a few early reports sug-
gesting slightly increased sensitivity compared to TEE and possibly a high negative 
predictive value. Limited evidence of their possible added clinical value, high costs, 
and limited availability so far has not resulted in recommended routine use and 
guidelines describe them as a possibility to consider in selected and complicated 
cases. The same approach is recommended for intracardiac echocardiography that 
possibly may enhance diagnostic accuracy, but just like TEE, is unable to distinguish 
thrombi from infective vegetations [7, 11, 30].
The role of ordinary chest X-ray has not been studied specifically. Guidelines rec-
ommend chest X-ray for patients presenting with acute symptoms as a baseline image 
during circumstances when full medical records may not be available [7]. Chest 
computerized tomography or pulmonary angiography can contribute in complicated 
diagnostic processes by finding septic emboli that constitute a minor Duke criterion.
9. Management
Successful management of CIED infection is dependent on complete and 
prompt device removal, long antimicrobial treatment, and reimplantation if the 
device is still indicated. In a few cases, device removal may not be possible, which 
substantially reduces the probability of curing the infection. There is a lack of ran-
domized controlled trials to guide management of CIED infection. Most of today’s 
practice is based on the results of observational studies or clinical expertise [25, 55].
In the case of suspected CIED infection, initially two or three blood cultures 
(depending on urgency) should be taken, followed by the initiation of empiric 
antibiotic treatment. After that, it is important to determine whether the device 
should be removed or not [7].
9.1 Device removal
Results from several retrospective studies have shown that complete and early 
device removal (despite its rare but potentially fatal complications) together with 
antibiotics is more effective than medical therapy alone with dramatically lower figures 
for mortality and infection relapse [9, 41, 56]. A multivariate analysis of a large CIED 
infection cohort showed a sevenfold increase in 30-day mortality for patients treated 
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with medical therapy alone compared to the combination with device removal [41]. In a 
large retrospective study of patients in Cleveland, 97% (pocket infection and CIED-IE) 
were cured by extraction combined with antibiotics [45]. Therefore, complete device 
removal is the general recommendation for established CIED infection [7, 11].
What is the implication of this for our previous presented clinical categories? 
The most benign case is that of post-implantation inflammation, where the device 
should not be removed. However, a close follow-up is important: what is first 
perceived as inflammation can later be interpreted as early symptoms of infection 
[7]. If symptoms instead are accordant with device pocket infection (complicated 
or uncomplicated), device removal is inevitable. That is also the case for the more 
extensive infections, definite CIED-LI and CIED-IE.
Remaining are two diagnostically more difficult categories: “possible CIED-LI” 
and “probable CIED infection” (occult bacteremia) for which guidelines recommend 
that device removal is considered while the patient is under continued observation 
with repeated echocardiography and blood cultures. Evaluation by physicians with 
specific expertise in CIED infection is always recommended when a diagnosis is estab-
lished, but is also an option for suspected infection if the investigation is complicated 
[11]. Additional radiology could strengthen a diagnosis in the case of complications 
of CIED infection such as septic arthritis, spine infection, pulmonary embolism, vein 
thrombosis, or metastatic abscess [7, 25]. If available, new modalities such as FDG-
positron emission tomography/computerized tomography might play a role by adding 
information in complex cases. In the case of bacteremia of an unknown source, all 
removable non-CIED sources of infection (such as intravenous lines) should be taken 
out [11]. A single positive blood culture without other symptoms is not sufficient for 
immediate device removal but the identified pathogen can give vital information. As 
mentioned in previous sections, CIED infection is more likely with Gram-positive 
bacteremia. S. aureus should not be neglected and instead always regarded as a 
possible pathogen, requiring further investigations in search of a source [11]. In the 
case of S. aureus bacteremia where there are no clinical or echocardiographic find-
ings supporting CIED infection, earlier American Heart Association guidelines have 
mentioned six parameters associated with CIED infection [14]:
• Relapsing bacteremia after finished antibiotic course.
• No other source of bacteremia is identified.
• Bacteremia persisting >24 h.
• The CIED is an ICD.
• The patient has a prosthetic valve.
• Bacteremia occurs within three months of device implantation.
A scientific statement from the Heart Rhythm Society stresses that early diagnosis 
and lead extraction Within three days of diagnosis were associated with lower mor-
tality in a small study [11, 40]. British guidelines recommend extraction as early as 
possible, but not later than within two weeks of diagnosis [7]. CIED infection can also 
occur for surgically implanted devices with epicardial leads. Basically, what has been 
stated for ordinary leads is also valid for epicardial leads. Complete device removal is 
recommended, after analyzing the risk of surgery for the individual patient compared 
to the risk from CIED infection. For localized pocket infection though, a practice of 
cutting the epicardial leads, only extracting the portion close to the pocket is used [11].
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9.2 Antibiotic treatment
For patients with suspected post-operative inflammation, the use of antibiot-
ics is controversial. It is reasonable to first consider if continued observation is 
sufficient. If needed, guidelines recommend a short oral course [7]. For all other 
clinical categories, some antimicrobial treatment is recommended. A multidisci-
plinary approach involving infectious disease specialists and individual adaptations 
depending on the patient’s risk factors and comorbidities is essential.
A basic principle is to start with broad empirical treatment, if systemic infection 
is suspected. At this stage, treatment should target both Gram-positive, includ-
ing methicillin-resistant S. aureus (MRSA), and Gram-negative bacteria [11]. The 
duration of antibiotic treatment is counted from the first negative culture after 
device removal and depends on a number of factors including the specific pathogen, 
extent of device infection, and existence of complications, if the device has been 
successfully removed or not. As with other parts of management, there is a lack of 
solid evidence and the choice of antibiotics and treatment durations are primarily 
based on expert opinion and experience [11]. Examples of regimens from current 
guidelines are provided in Tables 1 and 5, but it is also important to always consider 
local resistance patterns. The category “uncomplicated device pocket infection” by 
definition does not include systemic infection. However, some of these patients will 
eventually develop sepsis and therefore it is reasonable to start empiric therapy. Once 
a pathogen is identified through cultures, treatment should be modified accordingly.
9.3 Reimplantation
After removal of infected devices, it is crucial to always thoroughly reassess the 
need for a new CIED. Some patients no longer meet an original indication because of 
improvements in heart rhythm or function. Others have a strong personal opinion and 
do not accept a new implantation [11]. For some patients, another type of device can 
reduce possible risks of infection relapse (device downgrade and alternative devices are 
further described under prevention). The percentage of patients with CIED infection 
not requiring a replacement device has ranged from 13 to 52% in different studies [25].
Diagnosis/scenario Suggested 
antibiotics
Dose*
Pocket infection, 
uncomplicated
Vancomycin or 
daptomycin or 
teicoplanin
1 g q12h iv
4 mg/kg q24h iv
6 mg/kg to a 
maximum of 1 g 
given at 0.12 an 
24 h and then q24h
CIED-LI, CIED-IE, or 
complicated pocket 
infection, pending 
blood cultures, e.g. in 
sepsis
Vancomycin 
AND meropenem
or daptomycin 
AND meropenem
1 g q12 iv
1 g q8h
8–10 mg/kg q24h
1 g q8h iv
(appropriate spectrum, but risk of 
nephrotoxicity) (gentamicin in high 
dose, according to local guidelines, 
may be appropriate depending on 
local epidemiology) (less risk of 
nephrotoxicity than vancomycin)
CIED-LI or CIED-IE 
or complicated pocket 
infection with negative 
blood cultures
Vancomycin 
AND gentamicin 
or daptomycin 
AND gentamicin
1 g q12h iv
1 mg/kg q12h iv
8–10 mg/kg q24h
1 mg/kg q12h iv
(appropriate spectrum but risk of 
nephrotoxicity)
iv: intravenously, q8h: every 8 hours, q12h: every 12 hours, and q24h: every 24 hours.*All doses may require adjustment 
due to impaired renal function.
Table 5. 
Examples of guideline regimens for empiric antibiotic treatment.
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Clearance of infection is a prerequisite before hardware can be reimplanted. The 
optimal timing of reimplantation is however not known as no prospective trials 
have been done. According to recommendations from the Heart Rhythm Society, 
it is reasonable to await a 72 h period of negative blood cultures before reimplanta-
tion, also mentioning that there are single center studies indicating that reimplanta-
tion the same day as device extraction is possible for isolated pocket infections [11]. 
The existence of undrained abscesses or other sources of infection would demand 
further postponing of these suggested waiting times. It is also recommended that a 
new device is placed on the contralateral side, an attempt to reduce the risk of seed-
ing the new device from a prior tissue infection [9]. If remains of valvular infection 
are suspected, the waiting period should be extended to at least 14 days according 
to the European Society of Cardiology guidelines [5]. British guidelines, illustrating 
that there is no unanimity here, recommends reimplantation to whenever possible 
be delayed until signs of infection have resolved suggesting 7–10 days [7].
The pacemaker-dependent patient poses a special challenge. Some form of 
temporary pacing is needed as a bridge to reimplantation. Common problems of 
traditional temporary pacing are frequent loss of capture, undersensing, and that 
the systems in general are large and inconvenient, all this confining the patent to 
stay immobilized in a hospital bed during antibiotic treatment before reimplan-
tation. Studies of “semi-permanent” systems with active fixation leads and an 
external reusable pacemaker have shown that this practice is safe, reduces hospital 
stays, and makes the patient more mobile [11, 57]. However, these studies have so 
far only included a smaller number of patients and therefore are not able to rule out 
that the risks for relapsing infection earlier observed with temporary pacing still 
holds [58]. Therefore, all sorts of temporary pacing should still be regarded as a risk 
factor and avoided if possible, even though this semi-permanent technique prob-
ably is a way to reduce adverse events [5]. For ICD-patients with high risk of sudden 
cardiac death, the wearable cardioverter defibrillator can be a promising option. 
This noninvasive device is worn under normal clothing safely and effectively treats 
ventricular tachyarrhythmias, thus offering bridging to ICD reimplantation, (if the 
indication still holds) without increasing the risk of CIED infection relapse [59].
9.4 Management when device removal is not possible
Despite all known benefits of device removal, there are a small proportion of the 
patients that either decline device removal or are considered medically unfit for device 
removal. For many of these patients, it is likely that extraction will require surgical 
intervention and often they may be more or less dependent on a device (for instance 
CRT) that is not considered possible to reimplant. They may also have other, perma-
nent, sources of infection or a short life expectancy [11]. There is not much evidence 
to guide the management of these patients, but various smaller reports have described 
very varied outcomes. Some describe patients being cured with medical therapy 
alone. Others describe the strategy of partial device removal (only generator), which 
is possible for nonpacemaker-dependent patients, with cure rates in a wide range from 
13 to 71%. There are also reports of ICD patients with 100% failure [7].
British guidelines include regimens for attempts to salvage devices with medi-
cal therapy alone [7]. These consist of different combinations of antibiotics (for 
instance daptomycin and vancomycin), aiming to break through biofilm and are 
based on combinations that have salvaged infected non-CIED prosthetic materials 
and other devices. The duration of therapy is often 6 weeks. There is no known 
test to evaluate this therapy besides observation and blood cultures after the end 
of a course. Infection relapse is equivalent to a failure to salvage the device. In that 
case (unless the decision about device removal does not change), the only option 
is a palliative strategy of life-long suppressive antibiotic treatment. Patients in this 
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group are usually cardiovascularly stable and have responded well to antibiotics 
with clinical improvement and cleared bloodstream infection. This strategy can 
obviously only be applied to a few selected patients and the outcome is also unclear. 
Compared to curative strategies, this should be regarded as a last resort [11].
9.5 Risks associated with device removal
Device removal should be performed in specialized centers with expertise in the 
procedure and acute cardiac surgery backup available [30]. Percutaneous proce-
dures have become the most used method as procedural risks are lower compared 
to open surgery. In case of failures with a percutaneous technique, a conversion to 
open surgery is common. Removal of leads engrafted in cardiac tissue can be dan-
gerous. Over time, fibrous anchoring tends to develop between leads and vascular 
and cardiac structures. Inter-lead anchoring is also common. The major procedural 
complications are related to these anchorings and accidental tears or perforations 
of either the superior vena cava or parts of the myocardial wall with resulting dra-
matic bleeding and tamponade. Lead fracture often requires shifts to open surgery 
and can cause life threatening arrhythmias. To reduce risks, new techniques with 
locking stylets, photoablation of fibrous attachments, and less invasive methods 
aided by thoracoscopy have been developed [30, 60, 61]. In experienced centers, 
procedure mortality is low, between 0.1 and 0.6% [5]. If removal employs this 
type of special equipment, or concerns a lead implanted more than a year ago, the 
procedure is referred to as extraction as compared to explantation [11].
A number of procedural risk factors have been identified one of the more 
evident being elapsed time since lead implantation, which is related to the fibrous 
anchorings. Other risk factors are female sex, multiple leads (lead-lead anchoring), 
operator inexperience, and radiological findings of calcification involving leads. 
ICD is a risk factor as the device is bigger and more complex. In particular, the coils 
are suspected of stimulating fibrotic growth between device and myocardium and 
some extracting operators choose to only implant single coils for this reason [60].
In the case of very large vegetations, there is risk of pulmonary embolism. For 
very large vegetation, a shift to open surgery is common. There is uncertainty about 
how large vegetations should be for this shift to benefit the patient. Guidelines state 
that additional data are needed and recommend individualized decisions for vegeta-
tions >2 cm in diameter [5].
10. Prevention
As CIED infection results in substantial morbidity and mortality as well as high 
and rising costs for health care systems, good prevention is essential. The first 
subsection here is valid for all device patients. The following, covering secondary 
prevention, is specific for CIED infection patients. Being an essential and integrated 
part of all CIED infection management, it is not always specifically referred to as 
prevention. Finally, we give an outline of new therapies and devices with possible 
implications for all potential devices.
10.1 Primary prevention
Before implantation, the patient must be evaluated for clinical signs of infection. 
Fever during the last 24 h before implantation is a risk marker for later CIED infection. 
Signs of systemic infection should always result in elective implantations being post-
poned and acute procedures should be avoided until the infectious episode is resolved 
[7]. Perioperative antibiotics reduce the risk of infection. A randomized controlled 
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study was interrupted after having enrolled 649 patients, showing an infection rate of 
3.4% for the placebo group versus 0.6% in the antibiotics group [11]. When risk markers 
are studied, neglected perioperative antibiotics are one of the more consistent predictors 
of infection risk. Intravenous administration of a cephalosporin or penicillinase resis-
tant penicillin 1 h before procedural start or vancomycin 2 h before start are commonly 
used [11]. Repeated dosing after skin closure or general postoperative antibiotic use is 
not recommended. Except for TYRX™ (see Section 10.3), there is so far no support in 
evidence for local installation of antibiotics or antiseptics into the device pocket [7, 62].
Implantation should ideally take place in a designated CIED laboratory fulfilling 
requirements for ventilation suitable for device surgery. This is underlined by the 
fact that it is not unusual with perioperative CIED contamination today and many 
CIEDs are implanted in catheterization laboratories with lower ventilation require-
ments than operation theaters [7]. Implantation should be carried out with an aseptic 
technique, in an environment observing operating theater discipline. Alcoholic 
chlorhexidine (2%) should be used to prepare the skin over the operative site. Devices 
and surgical equipment should be left uncovered for the minimum possible time [7].
Risk of infection is also related to operator experience and the aggregated opera-
tion volumes of different centers—at least it has been shown that very small volumes 
are related to higher risk of complications: a study of Medicare recipients showed that 
physicians implanting 1–10 ICDs annually had higher complication rates than physi-
cians implanting more than 29 devices [63]. A US registry study found a complication 
rate of 3.8% at centers performing fewer than 24 implants a year compared to 3.1% 
at centers implanting more than 110 devices a year [64]. British guidelines stress the 
importance of supervision of junior operators (with lower operation volumes) by 
senior operators. They also speculate about if a lack of supervision is more common 
for generator exchange procedures, which have a higher risk of infection than de novo 
implants, but often are viewed as simple and “straightforward procedures” [7].
Postoperative hematomas are a consistently found risk factor. If possible, 
antithrombotic treatment and anticoagulation should be discontinued prior to the 
procedure. If a pause in anticoagulation is not deemed possible, it is however better 
to continue with ordinary warfarin doses than discontinuing and trying to bridge 
with heparin as this is related to a significant increase in pocket hematomas [7]. 
As for new oral anticoagulants (NOACs), there are less data, but studies suggest 
that there is no difference in pocket hematoma between interrupted and continued 
NOAC regimens [65].
10.2 Secondary prevention
The most effective preventive measure against CIED infection is to avoid 
unnecessary CIED implants in the first place. For patients with CIED infection, a 
reassessment of the risks and benefits of the device before reimplantation is crucial, 
and a significant proportion of the patients do actually not meet indications for 
reimplantation. As the risk is also associated with various properties of the device, 
this reevaluation can also result in a device downgrade, for instance from a more 
complex to a simpler device, or from two defibrillator coils to one on an ICD. An 
option is also to change from transvenous leads to epicardial leads, or more com-
monly, to choose some of the newer devices described below.
A general principle of CIED infections is to remove all hardware, but if this is 
not possible, as much as possible should be removed. Examples of the latter is the 
isolated removal of the generator for nonpacemaker-dependent patients who refuse 
lead extraction or the practice of cutting the leads and removing the proximal part 
together with the generator when epicardial lead extraction is regarded too risky, all 
based on the presumption that the generator accounts for the biggest infection bur-
den in a CIED and that its removal is a simple procedure compared to lead extraction.
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The risk of infection is less with peripheral cannulae than cuffed central 
venous catheters and patients can be treated with peripheral cannulae for very 
long periods, as long as the cannulae are changed every 72 h [66]. In fact, the risk 
of infection for any vascular access increases with time in situ. A central venous 
catheter also increases the risk of venous thrombosis reducing access options for 
future CIED placement. For some patients, though, siting cannulae can become 
very complicated and alternative strategies are needed as oral administration during 
CIED infection is not a safe procedure. Peripherally installed catheters (PICC or 
“midline”) may in that case be a better alternative than central venous catheters [7].
As mentioned in previous sections, temporary pacing with an intravenous pac-
ing wire is associated with higher risk of infection relapse and should if possible be 
avoided for CIED infection patients. If central venous catheters are used, potential 
future access sites for CIEDs (contralateral prepectoral to existing CIED) should be 
avoided if possible. Semi-permanent pacing with screw-in leads is probably better 
than traditional temporary pacing, but both techniques should be avoided unless 
the patient is dependent on pacing. It seems that this is not only valid for CIED 
infection patients (and thereby also an example of primary prevention); for acute 
patients, it is becoming more common to directly implant a pacemaker, rather than 
using temporary pacing with higher risk of future CIED infection [7, 58, 67].
10.3 Alternative device systems
A leadless pacemaker suitable for VVI-pacing can be implanted in the right 
ventricle through femoral venous access. It is a means of avoiding the traditional 
complications associated with leads or generator pockets, and studies have shown 
promising results with lower complication rates compared to transvenous CIEDs 
[68, 69]. However, to our knowledge, no randomized controlled studies have yet 
compared leadless and transvenous pacemakers. Also, no long-term studies have yet 
been completed. In situations with limited venous access as well as reimplantation 
after CIED infection for high risk patients, leadless pacing should be considered.
A subcutaneous ICD is an alternative to transvenous systems that can be con-
sidered as an option for reimplantation in patients with high risk of CIED infection 
relapse. With this system, complications related to leads or vascular access are 
avoided. It has proved to be as effective as an ordinary ICD in treating life-threaten-
ing arrhythmias, but it is unsuitable for patients needing pacing, resynchronization 
therapy, or antitachycardia pacing [70–72].
Since 2001, the noninvasive wearable cardioverter defibrillator has been avail-
able to provide temporary protection against sudden cardiac death. It safely and 
effectively detects and terminates ventricular arrhythmias and should be consid-
ered as a bridging therapy to ICD reimplantation. As a reassessment of the indica-
tions should take place before every reimplantation, the wearable cardioverter 
defibrillator also has the potential of bridging to a device downgrade [59, 73, 74].
In addition to perioperative systemic antibiotics, an antibiotic envelope 
(TYRX™) has been developed, wrapping the device and slowly releasing antibiot-
ics (minocycline and rifampin) in the device pocket. A meta-analysis of five prior 
studies including 4490 patients showed that use of the envelope is associated with 
significantly lowering the CIED infection rate, although the included studies were 
not randomized controlled trials [75]. Other studies have particularly showed ben-
efits among patients categorized as high risk individuals for early CIED infection 
(risk factors, Table 2) [76]. As the envelope is costly and its use is not yet routine, 
this selected patient group is probably the most promising to start with, although 
there are cost-benefit studies indicating a role for this envelope as a standard of care 
for all patients, at least in the context of the US health care system [77].
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Current evidence does not support the use of prophylactic antibiotics for 
dental procedures or other invasive procedures that do not involve direct device 
manipulation [11].
11. Conclusions
CIED infection is a rare but severe complication. As more complex devices are 
implanted in patients with more co-morbidities, the infection rate is on the rise. 
CIED infection should always be considered in device patients with unexplained 
fever—the presence of S. aureus bacteremia is equivalent to a risk of device infection 
of almost 50%. Once infection is established, renal impairment, old age, and endo-
carditis are some of the most consistently found predictors of mortality. Although 
not without lethal risks, device removal is the recommended treatment in all but a 
few cases and should be performed in designated centers. Combined with antibiotic 
treatment, this can enable cure rates as high as 97% according to some studies. 
Reassessment of the original indication should always precede device reimplantation. 
Intravenous lines and temporary pacing should be avoided if possible and technical 
alternatives such as leadless pacemakers, subcutaneous defibrillators, and antibiotic 
device envelopes should be considered as means of reducing risk of reinfection.
Abbreviations
CRT cardiac resynchronization therapy
CIED cardiac implantable electronic devices
CIED-IE CIED-associated infective endocarditis
CIED-LI lead infection
ICD implantable cardioverter defibrillator
IE infective endocarditis
NOAC new oral anticoagulant
MRSA methicillin-resistant S. aureus
TEE transesophageal echocardiography
TTE transthoracic echocardiography
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